ClinicalTrials.gg

Program

HCP1306

A development code. Also written as “HCP1306 5/10mg”, “HCP1306 10/10mg” and “HCP1306 20/10mg”.

Its studies are mostly in Hypercholesterolemia, led by Hanmi Pharmaceutical.

Furthest: phase 3, since Jul 30, 20146 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Hanmi Pharmaceutical61 open or runningphase 3since Jul 30, 2014Jul 30, 2014none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 30, 2014First study: phase 3 study in Primary HypercholesterolemiaFirst studyNCT02205606 · 412 enrolled · Korea, Republic of
  2. Oct 11, 2016Phase 1 study in Primary HypercholesterolemiaNCT02941848 · 60 enrolled
  3. Sep 2, 20192 phase 1 studies in HealthyNCT04081844, NCT04322266
  4. Jul 18, 2024Phase 1 study in HealthyNCT06518122 · 66 enrolled · Korea, Republic of
  5. Dec 9, 2025Phase 1 study in HealthyNCT07297693 · 60 planned · South Korea

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 6 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07297693Healthy · South Korea1Not yet recruitingMar 25, 202660
NCT06518122Healthy · Korea, Republic of1CompletedJan 3, 202566
NCT04322266Healthy · Korea, Republic of1CompletedFeb 13, 201961
NCT04081844Healthy · Korea, Republic of1CompletedJun 28, 201831
NCT02941848Primary Hypercholesterolemia1CompletedDec 201460
NCT02205606Primary Hypercholesterolemia · Korea, Republic of3CompletedFeb 2015412

How it is read

Names in the registry

  • “HCP1306”, 5 entries
  • “HCP1306 5/10mg”, 1 entry
  • “HCP1306 10/10mg”, 1 entry
  • “HCP1306 20/10mg”, 1 entry

Codes read as this program: HCP1306.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.